Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Public ClinicalTrials.gov record NCT00542451. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out what effect the postoperative combination of therapies: trastuzumab (herceptin) and paclitaxel (taxol) will have on breast cancer recurrence. A combination of trastuzuamb and chemotherapy has been used in women with node positive and high risk node negative disease. This tests utilizes a well tolerated regimen of weekly paclitaxel and trastuzumab in women with T1, node negative tumors that are HER2 positive. We would like to determine how effective this drug combination is when used in women with early stage breast cancer, as well as to better define the side effects of this treatment.
Study identification
- NCT ID
- NCT00542451
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 406 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2007 (Type not available)
- Primary completion
- Apr 21, 2014 (Actual)
- Completion
- Aug 30, 2022 (Actual)
- Last update posted
- Jun 26, 2024
2007 – 2022
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California-San Francisco | San Francisco | California | 94115 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| John Hopkins University | Baltimore | Maryland | 21231 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02115 | — |
| Dana-Farber at Faulkner Hospital | Boston | Massachusetts | 02130 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Cape Cod Healthcare | Hyannis | Massachusetts | 02601 | — |
| Lowell General Hospital | Lowell | Massachusetts | 01854 | — |
| North Shore Medical Center | Peabody | Massachusetts | 01960 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| North Shore LIJ Health System Monter Cancer Center | Lake Success | New York | 11042 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Duke Comprehensive Cancer Center | Durham | North Carolina | 27710 | — |
| Case Western University | Cleveland | Ohio | 44195 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| University of Vermont Cancer Center | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00542451, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2024 · Synced Oct 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00542451 live on ClinicalTrials.gov.